In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...

In systemic lupus erythematosus, chronic spontaneous urticaria did not raise SLEDAI scores, but cylindruria, mucosal ulcers, ...

A team from Peking Union Medical College Hospital in Beijing, China, have explored changes in the characteristics, treatment, and 5-year survival for SLE-associated PAH in the last decade, and ...

During the Phase IIb study (NCT05688696), 187 patients with SLE were randomised to receive 48 weeks of treatment with either 75mg or 50mg orelabrutinib or placebo. Within the 48-week treatment window, ...

A recent review published in Current Molecular Pharmacology explores the therapeutic potential of melatonin in systemic lupus erythematosus (SLE), a complex autoimmune disease affecting multiple ...

WASHINGTON — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications appear beneficial for people with systemic lupus erythematosus (SLE) and lupus nephritis, two new studies suggest. “The ...

Detailed mapping of CD4⁺ T cells from children with systemic lupus erythematosus (SLE) has revealed distinct immune cell subsets with likely roles in disease pathogenesis, according to a study led by ...

About 5 million people worldwide live with the autoimmune condition lupus. This condition can cause a range of symptoms, including tiredness, fever, joint pain and a characteristic butterfly-shaped ...

Objectives The European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of systemic lupus erythematosus (SLE) and lupus nephritis provide important guidance for ...